SG11202105279SA - Methods of treating myeloproliferative disorders - Google Patents

Methods of treating myeloproliferative disorders

Info

Publication number
SG11202105279SA
SG11202105279SA SG11202105279SA SG11202105279SA SG11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA
Authority
SG
Singapore
Prior art keywords
methods
myeloproliferative disorders
treating myeloproliferative
treating
disorders
Prior art date
Application number
SG11202105279SA
Inventor
Adrian Senderowicz
Michael Cooper
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of SG11202105279SA publication Critical patent/SG11202105279SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202105279SA 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders SG11202105279SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
SG11202105279SA true SG11202105279SA (en) 2021-06-29

Family

ID=64734125

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105279SA SG11202105279SA (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Country Status (8)

Country Link
JP (1) JP7453230B2 (en)
KR (1) KR20210095904A (en)
AU (1) AU2018451360B2 (en)
BR (1) BR112021010134A2 (en)
CA (1) CA3120973A1 (en)
EA (1) EA202191489A1 (en)
SG (1) SG11202105279SA (en)
WO (1) WO2020112086A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (en) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
US9969747B2 (en) 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide

Also Published As

Publication number Publication date
AU2018451360B2 (en) 2022-05-26
KR20210095904A (en) 2021-08-03
CA3120973A1 (en) 2020-06-04
AU2018451360A1 (en) 2021-06-10
JP2022519425A (en) 2022-03-24
BR112021010134A2 (en) 2021-08-24
JP7453230B2 (en) 2024-03-19
WO2020112086A1 (en) 2020-06-04
EA202191489A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods of treating fgf21-associated disorders
IL273693A (en) Treatment of inflammatory disorders
IL264510A (en) Methods and compositions for treatment of epileptic disorders
HK1259336A1 (en) Methods for treating myeloproliferative disorders
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
HK1256036A1 (en) Methods for treating myeloproliferative disorders
IL281736A (en) Methods of treating myeloproliferative disorders
IL267229A (en) Methods of treating ocular disorders
IL267818A (en) Methods for the treatment of neurological disorders
EP3621434A4 (en) Methods of treating neuropsychiatric disorders
IL275654A (en) Methods of treating disorders associated with castor
EP3897641C0 (en) Treatment of movement disorders
IL269604A (en) Pantids for treatment of autoimmune disorders
IL263080B (en) Treatment of neurological disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL281589A (en) Methods of treating myeloproliferative disorders
HK1245671A1 (en) Methods of using interleukin-10 for treating diseases and disorders
SG11202105279SA (en) Methods of treating myeloproliferative disorders
EP3654965C0 (en) Methods of treating autoimmune microvascular disorders
GB201604359D0 (en) Treatment of tissue disorders
IL268504A (en) Methods of treating seizure disorders
GB2580157B (en) Treatment of produced hydrocarbons
GB2580145B (en) Treatment of produced hydrocarbons
SG11202007642RA (en) Treatment of disorders with tasimelteon
IL274132A (en) Treatment of skin disorders